How Charlotte Trainer Beat Stage 4 Cancer at CHIPSA Hospital Charlotte Trainer thought she was out of options when she was diagnosed with Stage-4 inoperable Endometrial cancer in November of 2017. After having a full hysterectomy and 25 rounds of radiation, her doctors told her that the cancer had metastasized to her lungs. There was […]
Continue reading
A recent study published in Nature Genetics called “Tumor mutational load predicts survival after immunotherapy across multiple cancer types” revealed that tumors with more mutations had better results with immunotherapy treatment. The study looked at data from 1,662 metastatic cancer patients who received checkpoint inhibitor therapy, and data from over 5,000 patients who were not treated […]
Continue reading
People from all around the world are heading to CHIPSA Hospital in Mexico to treat their cancer. Our full-service community hospital overlooking the Pacific Ocean in Playas de Tijuana offers several integrative treatments and immunological therapies. We treat patients at all stages, including those with advanced, late-stage disease. It may seem like quite a journey […]
Continue reading
A research team from the University of Maryland is utilizing artificial intelligence (AI) to determine the most effective ways to treat cancer patients with immunotherapy. Immunotherapy takes advantage of the body’s own immune system to fight off cancer, and in the past decade, it has been very successful in treating patients with localized and advanced […]
Continue reading
The ORIENT-15 Phase 3 clinical trial evaluating Tyvyt (sintilimab injection) combined with chemotherapies Taxol (paclitaxel) and Platinol (cisplatin) as treatment for esophageal squamous cell carcinoma is now underway. Tyvyt was developed by Innovent Biologics and Eli Lilly and Company in China as an immune checkpoint inhibitor that will work against PD-1, a protein found on […]
Continue reading
Genetech has announced that the U.S. Food and Drug Administration (FDA) will be reviewing its Tecentriq (atezolizumab) combined with chemotherapy drugs Abraxane (nab-paclitaxel) and carboplatin for treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). The drug will be for patients without any mutations in the EGFR and ALK genes. Tecentriq is a checkpoint inhibitor drug that targets […]
Continue reading
Immune checkpoint inhibitors like Keytruda offer new ways to treat cancer patients who might otherwise have no options. But the treatment has posed challenges to health care professionals when it comes to figuring out which tumors will respond to immunotherapy and which tumors won’t. A research team at Memorial Sloan Kettering Cancer Center in New […]
Continue reading
Last September, 22 people made history as they joined together to celebrate accomplishing the impossible: surviving late-stage cancer. Traveling back to the place where their healing journeys began — CHIPSA Hospital in Tijuana, Mexico — the cancer survivors had the chance to share their stories, meet other patients, and converse with world-renowned doctors, scientists, coaches, […]
Continue reading
2018 saw tremendous improvements in immunotherapy methods that led to positive results for cancer patients all around the United States. 2019 promises even more advancements, and new strategies aim to increase these effective responses. The key to garnering even better immunotherapy results in 2019 will be using combination therapies. Two methods in particular will be front […]
Continue reading
In the past several years, many checkpoint inhibitors have been approved by the FDA for use in treating patients with metastatic bladder cancer. These drugs offer new options for doctors who are treating these patients, but they also pose the challenge of determining the best order in which to use them. Joaquim Bellmunt, MD, Ph.D., […]
Continue reading